verified SJR 1,78 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Oxford University Press

workspace_premium Q1 — Immunology and Allergy lock_open Open Access Unclaimed

Inflammatory Bowel Diseases

Inflammatory Bowel Diseases is a journal indexed in SJR in Immunology and Allergy and Gastroenterology with an H index of 183. It has an SJR impact factor of 1,78 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,78.

Inflammatory Bowel Diseases focuses its scope in these topics and keywords: inflammatory, bowel, disease, patients, crohn?s, clinical, colitis, response, pediatric, intestinal, ...

ISSN: 1078-0998

Editorial: Oxford University Press

Category: Immunology and Allergy

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

1,78 Q1

H-index 183

Tasa de Aceptación pie_chart

21% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

NPD Open Access

Ruta Non-OA 0 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

1,78

H-index

183

Docs (year)

320

Docs 3y

908

Total refs

9958

Cites 3y

3486

Citable 3y

683

Cites/Doc 2y

3.92

Ref/Doc

31.12

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

CAN A DOSE A DAY KEEP THE COLITIS AT BAY?

Writing Clinical Research Grant Applications

Cyclosporine, or Cyclosporine Not, for Severe Ulcerative Colitis

Current and past cigarette smoking significantly increase risk for microscopic colitis

Crohn's Jejunoileitis: The Pediatrician's Perspective on Diagnosis and Management

CROHN'S DISEASE AND IL-10 THERAPY: PROMISE REGAINED?

Comparative Phenotypic and CARD15 Mutational Analysis Among African American, Hispanic, and White Children with Crohn's Disease

Colonoscopic Findings in Intestinal Behçet's Disease

Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: Prevalence and risk factors

CHRONIC DIARRHEA: TO SCOPE OR NOT TO SCOPE?

Case Report: Crohn's Disease of the Mouse

CARD15 Mutation Analysis in an Italian Population

SHOW MORE ARTICLES

Cancer Risk in Collagenous Colitis

6-Mercaptopurine Is Effective in Crohn's Disease Without Concomitant Steroids

Butyrate Inhibits Leukocyte Adhesion to Endothelial Cells via Modulation of VCAM-1

BONES AND CROHN'S: SHOULD WE TREAT CROHN'S DISEASE PATIENTS WITH ALENDRONATE?

BMP-7: A New TGF-beta Family Member Takes the Stage in Colitis Treatment

Basic Epidemiology of Inflammatory Bowel Disease in Puerto Rico

Autoimmune Hemolytic Anemia Associated with Crohn's Disease

AN ENHANCED BARRIER IS A BETTER DEFENSE: EFFECTS OF PROBIOTICS ON INTESTINAL BARRIER FUNCTION

All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Pro

All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Con

All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment

A Shot in the Arm for Methotrexate

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.